Safety and Performance of the Elaspine System in the Treatment of the Lumbar Spine
NCT ID: NCT01323543
Last Updated: 2015-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2010-08-31
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Elaspine™
Impantation of Elaspine™ device
Elaspine™
Implantation of device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Elaspine™
Implantation of device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient is skeletally mature and between 21 - 80 years of age.
3. Patient's pre-operative Body Mass Index (BMI) is ≤ 34.
4. Patient's pre-operative Oswestry Disability Index (ODI) is ≥ 30% (≥15 out of 50 points).
5. Patient's pre-operative back pain Visual Analogue Scale (VAS) is \>60 (0-100 scale), with or without associated leg pain (leg pain VAS score).
6. Patient has received non-operative treatment for low back pain for \> 6 months and is unresponsive.
7. Patient has one or more of the following structural abnormalities with imaging studies verifying them at one or two contiguous levels within L1-L5:
* Discopathy
* Degenerative disc disease
* Massive or recurrent disc herniation
* Non-isthmic spondylolisthesis ≤ Grade 1 (acc. To Meyerding)
* Spinal stenosis
* Partially defective facet joints
* Retrolisthesis according to one of the following definitions (acc. to Ruch, William J.; Literature Reference 21):
* Complete Retrolisthesis: The body of one vertebra is posterior to both the vertebral body of the segment of the spine above as well as below
* Stairstepped Retrolisthesis: The body of one vertebra is posterior to the body of the spinal segment above, but is anterior to the one below.
* Partial Retrolisthesis: The body of one vertebra is posterior to the body of the spinal segment either above or below.
Exclusion Criteria
2. Need for more than two-level or two non-contiguous-level surgery in the lumbar spine.
3. Patient has more than 50% defective facet joint (half of the articular joint surface) or laminectomy
4. Patient is scheduled for another lumbar surgery such as but not limited to a fusion
5. Patient has recent vertebral fractures or past fractures which did not heal.
6. Patient has known allergies to titanium alloy and polycarbonate urethane (PCU).
7. Patient has clinically compromised vertebral body structure and morphology at the lumbar spine due to current or past trauma (or pathological vertebral fracture) or significant endplate incompetence such as Schmorl´s node.
8. Patient has spondylolysis at the levels to be treated or an adjacent level.
9. Patient has a frontal curve in the lumbar spine \>10°.
10. Patient has previously been diagnosed osteopenia or metabolic bone diseases or severe osteoporosis - if suspected to be confirmed by bone density being 2.5 SD below normal as assessed using DEXA analysis in:
* Postmenopausal females if suggested by x-ray or other risk factors
* Males over the age of 60 that have sustained a non-traumatic hip or spine fracture
11. Patient is taking medications known to potentially interfere with bone/soft tissue healing, including but not limited to the long term use of corticosteroids. (This is not intended to exclude patients using inhalation medications for asthma.)
12. Patient has an active infection either systemic or at the local site of intended surgery.
13. Patient has been diagnosed with hepatitis, rheumatoid arthritis, an autoimmune disease, or AIDS, ARC, or is HIV positive or any other diseases that according to surgeons may have an impact on the outcome of the surgery.
14. Patients with known malignant diseases or bone tumors.
15. Patients with vascular malformations such as abdominal aneurysm.
16. Patient has a progressive neuromuscular disease. Patient has active malignancy within the last 15 years, unless the malignancy was treated with curative intent and there have been no clinical signs or symptoms for at least 5 years.
17. Patient has cervical myelopathy.
18. Patient is pregnant or planning in becoming pregnant in the next 2 years.
19. Patient is currently participating in another investigational study where the endpoints have not yet been achieved. 8/35 Elaspine™ PMCS 01, Clinical Investigation Plan CIP EN Version C, October 1st, 2010 CONFIDENTIAL
20. Patient has mental illness, and/or diagnosed as clinically depressed or belongs to a vulnerable population (e.g., prisoner, severe drug abuser, developmentally disabled) that would compromise ability to provide informed consent or compliance with follow-up requirements. If suspected to be confirmed by classification according to DSM IV.
21. Patient has had another surgical procedure(s) within the last 60 days involving general anesthesia or any surgical procedure that might increase the risk of deep vein thrombosis.
22. Loss of Disk height according to Pfirrmann (\> C) or Frymoyer (\>3) and or severe spondylosis.
23. Patient shows three or more signs of anorganic behaviour (Waddell´s signs).
21 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UL International GmbH
UNKNOWN
Spinelab AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Helios Rosmann Klinik
Breisach, Baden-Wurttemberg, Germany
Stauferklinikum Schwäbisch Gmünd
Mutlangen, Baden-Wurttemberg, Germany
HSK Dr. Horst-Schmidt-Klinik
Wiesbaden, Hessia, Germany
Katholisches Klinikum Marienhof
Koblenz, Rhineland-Palatinate, Germany
HUG Hôpitaux Universitaires de Genève
Geneva, Canton of Geneva, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10k002 PMCS 01
Identifier Type: -
Identifier Source: org_study_id